Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year
A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.
Vincent Jiangthree-minute read
Eli Lilly−2.15% — Eli Lilly, down 2.15 percent today agreed to buy Calytrix Bio, a closely held developer of treatments for rare blood cancers, in a deal worth up to $1.5 billion, the latest move in a $32 billion wave of acquisitions this year as the drugmaker builds out cancer and immunology businesses ahead of the patent cliff on Zepbound and Mounjaro 1. Days earlier, on November 16, it signed agreements with Stipple Bio and Calytrix carrying a combined potential value of about $7.4 billion, including milestone-contingent payments 2.
How much of that headline is cash versus promise is exactly what the filings do not itemize. Bloomberg reports Lilly has stuck to earlier-stage, cheaper deals 1, and none of what it has bought this year has reached approval, as far as the record shows 1.
The cash engine is real, and it is already running down
The checkbook behind the spree is genuine. Lilly's third-quarter revenue rose 39% to $24.4 billion, with volume up 53% offsetting a 15% slide in realized prices 3. Operating cash flow hit $11.4 billion in the quarter, more than four times the $2.5 billion of late 2024, per its SEC filings 5.
Eli Lilly's quarterly operating cash flow more than quadrupled since late 2024
The quarterly cash engine more than quadrupled since late 2024
Data
| Operating cash flow | |
|---|---|
| Q4 '24 | 2.47B |
| Q1 '25 | 1.67B |
| Q2 '25 | 3.09B |
| Q3 '25 | 8.84B |
| Q4 '25 | 3.23B |
| Q1 '26 | 5.33B |
| Q2 '26 | 10.69B |
| Q3 '26 | 11.4B |
But the filings also show the pile thinning. Cash on the balance sheet fell from $9.8 billion in September 2025 and $8.95 billion at mid-2026 to $4.9 billion at the end of September, while debt stood at about $49.5 billion 5. What has not left yet is the promise side: the largest single check of 2026 is just above $7 billion, and Calytrix's headline $1.5 billion is an "up to" figure 1.
Cash on hand has fallen by half since September 2025 while debt climbed to $49.5 billion
- Cash on hand
- Total debt
Data
| Cash on hand | Total debt | |
|---|---|---|
| Q3 '24 | $3.37B | $31.12B |
| Q4 '24 | $3.27B | $33.64B |
| Q1 '25 | $3.09B | $38.52B |
| Q2 '25 | $3.38B | $39.9B |
| Q3 '25 | $9.79B | $42.51B |
| Q4 '25 | $7.27B | $42.5B |
| Q1 '26 | $5.28B | $43.37B |
| Q2 '26 | $8.95B | $54.91B |
| Q3 '26 | $4.89B | $49.5B |
The deal charges are already inside the guidance
The bill for acquired research is already in the guidance: the third quarter carried $4.57 a share of acquired in-process research and development charges, the accounting line where deal costs hit earnings, and the full-year EPS guide of $35 to $36 includes them 3.
The market is marking down the acquirer
Lilly's stock closed at $1,382.75 on November 18, down 2.32%, a third straight loss and 6.27% below its November 16 high of $1,475.25 2. At that price the shares trade near 31 times forward earnings against a 5-year average of 40x, and Barclays'−1.00% — Barclays, down 1.00 percent today raised $1,550 target leaves about 9% upside 3.
Whether the contingent payments end up settled in cash or in shares is not disclosed; the open question is whether Lilly is funding a decade-ahead pipeline with an $11 billion quarterly cash engine, or with a stock the market is repricing 1. Management's own answer is history: Prozac's patent expiry sent Lilly into what Bloomberg calls a dark period, and the spending is insurance against a repeat, with roughly a decade left on the GLP-1 patents 1.
December 7 and January are the ledger dates
Innovation Day on December 7 is where management must show growth beyond obesity, and January's first 2027 guidance must show volume still outrunning falling prices 3. The cyber-extortion claims around a third-party vendor, which Lilly says did not touch its systems, are noise next to that 2. The number to watch is not the deal headlines. It is whether $11 billion a quarter of operating cash flow can absorb a $32 billion year of "up to" promises without another draw on debt 5.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.






Reader comments
0 comments